Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
Serotonin (5-HT) plays an important role in the regulation of several basic functions of the central and peripheral nervous system. Among the 5-HT receptors, serotonin-6 (5-HT<sub>6</sub>) receptor has been an area of substantial research. 5-HT<sub>6</sub> receptor is a G-pro...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/2/309 |
| _version_ | 1797622171667791872 |
|---|---|
| author | Ramakrishna Nirogi Pradeep Jayarajan Anil Shinde Abdul Rasheed Mohammed Venkata Ramalingayya Grandhi Vijay Benade Vinod Kumar Goyal Renny Abraham Venkat Jasti Jeffrey Cummings |
| author_facet | Ramakrishna Nirogi Pradeep Jayarajan Anil Shinde Abdul Rasheed Mohammed Venkata Ramalingayya Grandhi Vijay Benade Vinod Kumar Goyal Renny Abraham Venkat Jasti Jeffrey Cummings |
| author_sort | Ramakrishna Nirogi |
| collection | DOAJ |
| description | Serotonin (5-HT) plays an important role in the regulation of several basic functions of the central and peripheral nervous system. Among the 5-HT receptors, serotonin-6 (5-HT<sub>6</sub>) receptor has been an area of substantial research. 5-HT<sub>6</sub> receptor is a G-protein-coupled receptor mediating its effects through diverse signaling pathways. Exceptional features of the receptors fueling drug discovery efforts include unique localization and specific distribution in the brain regions having a role in learning, memory, mood, and behavior, and the affinity of several clinically used psychotropic agents. Although non-clinical data suggest that both agonist and antagonist may have similar behavioral effects, most of the agents that entered clinical evaluation were antagonists. Schizophrenia was the initial target; more recently, cognitive deficits associated with Alzheimer’s disease (AD) or other neurological disorders has been the target for clinically evaluated 5-HT<sub>6</sub> receptor antagonists. Several 5-HT<sub>6</sub> receptor antagonists (idalopirdine, intepirdine and latrepirdine) showed efficacy in alleviating cognitive deficits associated with AD in the proof-of-concept clinical studies; however, the outcomes of the subsequent phase 3 studies were largely disappointing. The observations from both non-clinical and clinical studies suggest that 5-HT<sub>6</sub> receptor antagonists may have a role in the management of neuropsychiatric symptoms in dementia. Masupirdine, a selective 5-HT<sub>6</sub> receptor antagonist, reduced agitation/aggression-like behaviors in animal models, and a post hoc analysis of a phase 2 trial suggested potential beneficial effects on agitation/aggression and psychosis in AD. This agent will be assessed in additional trials, and the outcome of the trials will inform the use of 5-HT<sub>6</sub> receptor antagonists in the treatment of agitation in dementia of the Alzheimer’s type. |
| first_indexed | 2024-03-11T09:06:32Z |
| format | Article |
| id | doaj.art-ffb38ef38eaf41d680d033f6aa4d190b |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-11T09:06:32Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-ffb38ef38eaf41d680d033f6aa4d190b2023-11-16T19:23:21ZengMDPI AGBiomolecules2218-273X2023-02-0113230910.3390/biom13020309Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain DisordersRamakrishna Nirogi0Pradeep Jayarajan1Anil Shinde2Abdul Rasheed Mohammed3Venkata Ramalingayya Grandhi4Vijay Benade5Vinod Kumar Goyal6Renny Abraham7Venkat Jasti8Jeffrey Cummings9Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500034, Telangana, IndiaSuven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500034, Telangana, IndiaSuven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500034, Telangana, IndiaSuven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500034, Telangana, IndiaSuven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500034, Telangana, IndiaSuven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500034, Telangana, IndiaSuven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500034, Telangana, IndiaSuven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500034, Telangana, IndiaSuven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500034, Telangana, IndiaChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV 89154, USASerotonin (5-HT) plays an important role in the regulation of several basic functions of the central and peripheral nervous system. Among the 5-HT receptors, serotonin-6 (5-HT<sub>6</sub>) receptor has been an area of substantial research. 5-HT<sub>6</sub> receptor is a G-protein-coupled receptor mediating its effects through diverse signaling pathways. Exceptional features of the receptors fueling drug discovery efforts include unique localization and specific distribution in the brain regions having a role in learning, memory, mood, and behavior, and the affinity of several clinically used psychotropic agents. Although non-clinical data suggest that both agonist and antagonist may have similar behavioral effects, most of the agents that entered clinical evaluation were antagonists. Schizophrenia was the initial target; more recently, cognitive deficits associated with Alzheimer’s disease (AD) or other neurological disorders has been the target for clinically evaluated 5-HT<sub>6</sub> receptor antagonists. Several 5-HT<sub>6</sub> receptor antagonists (idalopirdine, intepirdine and latrepirdine) showed efficacy in alleviating cognitive deficits associated with AD in the proof-of-concept clinical studies; however, the outcomes of the subsequent phase 3 studies were largely disappointing. The observations from both non-clinical and clinical studies suggest that 5-HT<sub>6</sub> receptor antagonists may have a role in the management of neuropsychiatric symptoms in dementia. Masupirdine, a selective 5-HT<sub>6</sub> receptor antagonist, reduced agitation/aggression-like behaviors in animal models, and a post hoc analysis of a phase 2 trial suggested potential beneficial effects on agitation/aggression and psychosis in AD. This agent will be assessed in additional trials, and the outcome of the trials will inform the use of 5-HT<sub>6</sub> receptor antagonists in the treatment of agitation in dementia of the Alzheimer’s type.https://www.mdpi.com/2218-273X/13/2/309clinical trials5-HT<sub>6</sub> receptor antagonistavisetroncerlapirdineidalopirdineintepirdine |
| spellingShingle | Ramakrishna Nirogi Pradeep Jayarajan Anil Shinde Abdul Rasheed Mohammed Venkata Ramalingayya Grandhi Vijay Benade Vinod Kumar Goyal Renny Abraham Venkat Jasti Jeffrey Cummings Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders Biomolecules clinical trials 5-HT<sub>6</sub> receptor antagonist avisetron cerlapirdine idalopirdine intepirdine |
| title | Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders |
| title_full | Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders |
| title_fullStr | Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders |
| title_full_unstemmed | Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders |
| title_short | Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders |
| title_sort | progress in investigational agents targeting serotonin 6 receptors for the treatment of brain disorders |
| topic | clinical trials 5-HT<sub>6</sub> receptor antagonist avisetron cerlapirdine idalopirdine intepirdine |
| url | https://www.mdpi.com/2218-273X/13/2/309 |
| work_keys_str_mv | AT ramakrishnanirogi progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders AT pradeepjayarajan progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders AT anilshinde progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders AT abdulrasheedmohammed progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders AT venkataramalingayyagrandhi progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders AT vijaybenade progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders AT vinodkumargoyal progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders AT rennyabraham progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders AT venkatjasti progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders AT jeffreycummings progressininvestigationalagentstargetingserotonin6receptorsforthetreatmentofbraindisorders |